Literature DB >> 15958248

Integrating hepatitis, STD, and HIV services into a drug rehabilitation program.

Robert A Gunn1, Marjorie A Lee, David B Callahan, Patricia Gonzales, Paula J Murray, Harold S Margolis.   

Abstract

BACKGROUND: Considering the difficulties in providing screening and vaccination services for inmates in short-stay incarceration facilities, an evaluation was conducted of the integration of prevention services in an alternative sentencing drug rehabilitation program (alternative to incarceration) in San Diego CA.
METHODS: During the period April 1999 to December 2002, clients were asked to complete a brief risk-assessment questionnaire, and were offered hepatitis B virus (HBV) vaccination, HBV and hepatitis C virus (HCV) serologic testing, STD screening, and HIV counseling and testing.
RESULTS: Of the estimated 1125 rehabilitation program enrollees, 930 (83%) participated in the integration program services. Most clients were male (64%), were aged >30 years (64%), and few (7%) reported previous HBV vaccination. Of the 854 clients eligible for hepatitis B vaccination, 98% received the first dose, 69% the second dose, and 42% completed the series. Eleven percent of clients had prior HBV infection, and 14.7% had HCV infection, with positivity rates being highest among those with a history of injection drug use-HBV, 19%, and HCV, 36%. HIV infection was rare (prevalence, 0.3%), and STDs were uncommon (chlamydia prevalence, 2%, and gonorrhea prevalence, 0.6%). Total annual cost of integration services (excluding HIV testing) was dollar 31,994 equating to dollar 122 per client served.
CONCLUSIONS: Alternative sentencing drug rehabilitation programs provide a venue to efficiently deliver integrated hepatitis and other prevention services. Considering the vast number of high-risk persons in drug rehabilitation, probation, parole, and inmate release programs, an opportunity exists to greatly expand hepatitis services.

Entities:  

Mesh:

Year:  2005        PMID: 15958248     DOI: 10.1016/j.amepre.2005.03.010

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  11 in total

Review 1.  Behavior change and health-related interventions for heterosexual risk reduction among drug users.

Authors:  Salaam Semaan; Don C Des Jarlais; Rob Malow
Journal:  Subst Use Misuse       Date:  2006       Impact factor: 2.164

Review 2.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

3.  Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services.

Authors:  Laurie Sylla; R Douglas Bruce; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2007-05-10

4.  Unknown quantities: HIV, viral hepatitis, and sexually transmitted infections in community corrections.

Authors:  Sarah Larney; Sheryl Hado; Michelle McKenzie; Josiah D Rich
Journal:  Sex Transm Dis       Date:  2014-04       Impact factor: 2.830

5.  Does integrating viral hepatitis services into a public STD clinic attract injection drug users for care?

Authors:  Robin R Hennessy; Isaac B Weisfuse; Karen Schlanger
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

6.  The relative role of perceived partner risks in promoting condom use in a three-city sample of high-risk, low-income women.

Authors:  Allison J Ober; Martin Y Iguchi; Robert E Weiss; Pamina M Gorbach; Robert Heimer; Lawrence J Ouellet; Steven Shoptaw; M Douglas Anglin; William A Zule
Journal:  AIDS Behav       Date:  2011-10

Review 7.  Preconception care for improving perinatal outcomes: the time to act.

Authors:  Hani K Atrash; Kay Johnson; Myron Adams; José F Cordero; Jennifer Howse
Journal:  Matern Child Health J       Date:  2006-06-14

8.  Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion.

Authors:  Carissa E Chu; Feng Wu; Xi He; Kali Zhou; Yu Cheng; Weiping Cai; Elvin Geng; Paul Volberding; Joseph D Tucker
Journal:  Open Forum Infect Dis       Date:  2016-06-24       Impact factor: 3.835

9.  Hepatitis vaccination of men who have sex with men at gay pride events.

Authors:  Erik David Storholm; Dennis G Fisher; Grace L Reynolds; Lucy E Napper; Timothy A Morrisse; Lee M Kochems
Journal:  Prev Sci       Date:  2010-06

10.  Reasons for Nonattendance across the Hepatitis C Disease Course.

Authors:  Gail Butt; Liza McGuinness; Terri Buller-Taylor; Sandi Mitchell
Journal:  ISRN Nurs       Date:  2013-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.